*Support for orders is not given over Facebook, please use the ticket system on this website.
M., Meehan, J
Back to Journals Diabetes, Metabolic Syndrome and Obesity Volume 19 GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists Authors Abid M, Sheikh KS, Ahmad MS, Jiang H Received 19 January 2026 Accepted for publication 17 March 2026 Published 12 June 2026 Volume 2026:19 566414 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Donald McClain Mahroz Abid, 1 Khizer Sohail Sheikh, 1 Muhammad Shahbaz Ahmad, 2 Hongwei Jiang 1 1 Department of Metabolism and Endocrinology, Endocrine and Metabolic Disease Center, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Peoples Republic of China
GLP-1 receptor agonists, such as Ozempic, function by emulating the effects of GLP-1 hormones, which are naturally produced in the body and control the release of insulin in response to food consumption